Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food-effect of XS003 vs Tasigna in Healthy Males
NCT02068898Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Dec 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of XS003 in chronic myeloid leukemia (CML) (4 arms), sponsored by Xspray Pharma. Primary endpoint: Bioavailability of Nilotinib at 3 days. Started Dec 2013; status: completed.
02
Drugs
XS003
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02068898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068898.